Quality of life (QoL) of patients with breast cancer is not dependent only on the presence of the disease, as there is such a multitude of social and clinical factors \[[@CIT0001], [@CIT0002]\]. However, data on the determinants of QoL in Polish breast cancer patients during the course of radiotherapy are scarce and based on custom-made questionnaires \[[@CIT0003]\], rather than the EORTC QLQ-C30 or QLQ-BR23, which are the tools of choice for such patients \[[@CIT0004], [@CIT0005]\]. We evaluated breast cancer patients undergoing radiotherapy for treatment-related determinants of QoL and compared them with the intensity of depressive symptoms.

A total of 98 women with breast cancer during the standard course of external beam radiotherapy agreed to complete the validated Polish versions 3.0 of EORTC QLQ-C30, QLQ-BR23 (all global, functional and symptom scales) and -- at the same time point -- the Beck Depression Inventory (BDI) to evaluate the intensity of depressive symptoms. A control group of 127 healthy women referred to the mammography department for screening purposes was evaluated using the BDI.

Median age of the study group was 54 (25--75%: 46.7--60.5) years. Breast conserving therapy (BCT) had been performed in 50% of patients. In the breast cancer group, 65% of subjects had undergone some form of chemotherapy and 51% were undergoing hormone therapy. Cronbach\'s α values for QLQ-C30, QLQ-BR23 and BDI were 0.91, 0.81 and 0.83 respectively, confirming adequate test performance.

Median total radiation dose given to the patients was 34 Gy (25--75%: 18--42 Gy), and only affected intensity of nausea/vomiting and constipation subscales (*R* = 0.25, *p* = 0.04; *R* = 0.27, *p* = 0.03 respectively) of the QLQ-C30 functional scales. No statistically significant correlations were found between the total dose and QLQ-BR23 scales, but the early reactions (RTOG staged ≥ 2 \[[@CIT0006]\]) significantly worsened arm symptom subscale score assessment in QLQ-BR23.

Hormonal therapy was not significantly correlated with any of those three questionnaires' subscores. Previously received chemotherapy impacted neither QLQ-C30 nor BDI results, but it was associated with body image (BRBI) and systemic therapy side effect scores (BRST) (*p* = 0.02 and *p* = 0.005). Type of surgical intervention before radiotherapy impacted the field of global health status, resulting in better overall QoL in patients who had undergone BCT (58% (25--75%: 50--67) vs. 50% (25--75%: 42--58); *p* = 0.0405). BCT was also associated with lower reported intensity of breast symptoms (*p* = 0.0338) and better perception of future perspectives (BRFU; *p* = 0.0328). The level of depressive symptoms measured in controls was significantly lower than in cancer patients (median 5 (25--75%: 1--10) vs. 12 (25--75%: 6--17) points; *p* \< 0.0001). BDI scores were correlated negatively and significantly with all functional scales of QLQ-C30 (Spearman\'s correlation coefficients ranging from --0.36 to --0.46, all *p* \< 0.05) and QLQ-BR23 subscales: BRBI and BRFU (*R* = --0.47 and --0.51; *p* \< 0.05).

In conclusion, radiotherapy itself has a minor influence on QoL of breast cancer patients, although organ-specific complications may significantly impair physical functioning. Other forms of oncological treatment, such as the type of surgical procedure performed, have a much more profound impact on all fields of QoL. Intensity of depressive symptoms is an important determinant of QoL in cancer patients which mandates routine psychological evaluation.
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